Efendioğlu Mustafa, Şanli Elif, Türkoğlu Ceren, Balak Naci
Department of Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
Koç University School of Medicine, Istanbul, Turkey.
Noro Psikiyatr Ars. 2021 Jun 3;58(2):133-136. doi: 10.29399/npa.27536. eCollection 2021 Jun.
High-grade gliomas (HGG), including Glioblastoma multiforme (GBM), account for the majority of primary brain tumors. Nevertheless, prognostic and diagnostic biomarkers are quite limited for HGG. The objective of this study was to investigate the prognostic value of sRANKL and sTREM2 levels in HGG patients.
Twelve consecutive patients with HGG, 14 patients with non-glial tumors (non-GT) and 20 age and gender-matched healthy controls were recruited. Overall survival duration of the patients was recorded. Pre-operative serum levels of sRANKL and sTREM2 were measured by ELISA. Tumors of HGG patients were analyzed by immunohistochemical staining for p53 and Ki67 and percentage scores were calculated.
Patients with HGG and non-GT showed lower serum sRANKL and sTREM2 levels than healthy individuals. Levels of sRANKL were inversely correlated with the overall survival of patients (p=0.002, R=0.787), while sTREM2 levels were inversely correlated with p53 score (p=0.018, R=-0.666) but not survival.
Brain tumor patients show suppressed levels of glial activity biomarkers in the peripheral circulation. Serum sRANKL levels may serve as a potential prognostic biomarker for HGG.
高级别胶质瘤（HGG），包括多形性胶质母细胞瘤（GBM），占原发性脑肿瘤的大多数。然而，HGG的预后和诊断生物标志物相当有限。本研究的目的是探讨sRANKL和sTREM2水平在HGG患者中的预后价值。
招募了12例连续的HGG患者、14例非胶质肿瘤（非GT）患者以及20例年龄和性别匹配的健康对照。记录患者的总生存时间。术前血清sRANKL和sTREM2水平通过酶联免疫吸附测定（ELISA）进行测量。对HGG患者的肿瘤进行p53和Ki67免疫组织化学染色分析并计算百分比评分。
HGG患者和非GT患者的血清sRANKL和sTREM2水平低于健康个体。sRANKL水平与患者的总生存呈负相关（p = 0.002，R = 0.787），而sTREM2水平与p53评分呈负相关（p = 0.018，R = -0.666），但与生存无关。
脑肿瘤患者外周循环中的胶质细胞活性生物标志物水平受到抑制。血清sRANKL水平可能作为HGG的潜在预后生物标志物。
